Drugs List

Therapeutic Indications

Uses

Myeloma - multiple

Treatment of multiple myeloma in combination with lenalidomide and dexamethasone in adult patients who have received at least one prior therapy.

Treatment of relapsed and refractory multiple myeloma in combination with pomalidomide and dexamethasone in adult patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy.

Dosage

Due to the complexity and specialist nature of dosage regimens for the treatment of malignant disease, specific dosing information on this agent is not included.
Doses may vary significantly if this agent is used as monotherapy or different combinations.
When using this agent, specialist literature, national guidelines, cancer network protocols and Trust chemotherapy protocols should be consulted.

Administration

For intravenous infusion only.

Contraindications

Children under 18 years
Breastfeeding
Pregnancy

Precautions and Warnings

Females of childbearing potential
Serum bilirubin above 1.5 times upper limit of normal

Advise ability to drive/operate machinery may be affected by side effects
Combination therapy: refer to information for concomitant agent
Pre-medicate with corticosteroids, antihistamines and H2 antagonists
Premedication with antipyretic recommended
Treatment to be initiated and supervised by a specialist
Consult local policy on the safe use of anti-cancer drugs
Must be given as an intravenous infusion
Record name and batch number of administered product
Staff: Not to be handled by pregnant staff
Monitor closely any patient who develops new infection while on treatment
Monitor patient throughout infusion and for at least 2 hours afterwards
Monitor patients for development of second primary malignancies
Advise patient to report symptoms of infection immediately
Interrupt therapy/reduce infusion rate if infusion-related reactions occur
May affect results of some laboratory tests
Discontinue if grade 3 or higher infusion reaction occurs
Female: Contraception required during and for 120 days after treatment
Male: Contraception required during and for 6 months after treatment

Pregnancy and Lactation

Pregnancy

Elotuzumab is contraindicated during pregnancy.

The manufacturer recommends that elotuzumab should not be used during pregnancy unless the clinical condition of the woman requires it. Elotuzumab is given in combination with lenalidomide or pomalidomide, which are contraindicated during pregnancy. Refer to lenalidomide and pomalidomide product information for details of the pregnancy prevention programme.

Lactation

Elotuzumab is contraindicated during breastfeeding.

The manufacturer recommends that breastfeeding should be stopped during treatment with elotuzumab due to the combination treatment with lenalidomide or pomalidomide. Elotuzumab is not expected to be excreted in human milk however as it is given in combination with lenalidomide or pomalidomide, breastfeeding should be discontinued during treatment.

Side Effects

Anaphylactic reaction
Chest pain
Cough
Deep vein thrombosis (DVT)
Diarrhoea
Fatigue
Headache
Herpes zoster
Hypersensitivity reactions
Hypoaesthesia
Infusion related reaction
Leukopenia
Lymphopenia
Mood changes
Nasopharyngitis
Night sweats
Oropharyngeal pain
Pneumonia
Pyrexia
Upper respiratory tract infection
Weight loss

Presentation

Infusions of elotuzumab.

Drugs List

Therapeutic Indications

Uses

Myeloma - multiple

Treatment of multiple myeloma in combination with lenalidomide and dexamethasone in adult patients who have received at least one prior therapy.

Treatment of relapsed and refractory multiple myeloma in combination with pomalidomide and dexamethasone in adult patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy.

Dosage

Due to the complexity and specialist nature of dosage regimens for the treatment of malignant disease, specific dosing information on this agent is not included.
Doses may vary significantly if this agent is used as monotherapy or different combinations.
When using this agent, specialist literature, national guidelines, cancer network protocols and Trust chemotherapy protocols should be consulted.

Administration

For intravenous infusion only.

Contraindications

Children under 18 years
Breastfeeding
Pregnancy

Precautions and Warnings

Females of childbearing potential
Serum bilirubin above 1.5 times upper limit of normal

Advise ability to drive/operate machinery may be affected by side effects
Combination therapy: refer to information for concomitant agent
Pre-medicate with corticosteroids, antihistamines and H2 antagonists
Premedication with antipyretic recommended
Treatment to be initiated and supervised by a specialist
Consult local policy on the safe use of anti-cancer drugs
Must be given as an intravenous infusion
Record name and batch number of administered product
Staff: Not to be handled by pregnant staff
Monitor closely any patient who develops new infection while on treatment
Monitor patient throughout infusion and for at least 2 hours afterwards
Monitor patients for development of second primary malignancies
Advise patient to report symptoms of infection immediately
Interrupt therapy/reduce infusion rate if infusion-related reactions occur
May affect results of some laboratory tests
Discontinue if grade 3 or higher infusion reaction occurs
Female: Contraception required during and for 120 days after treatment
Male: Contraception required during and for 6 months after treatment

Pregnancy and Lactation

Pregnancy

Elotuzumab is contraindicated during pregnancy.

The manufacturer recommends that elotuzumab should not be used during pregnancy unless the clinical condition of the woman requires it. Elotuzumab is given in combination with lenalidomide or pomalidomide, which are contraindicated during pregnancy. Refer to lenalidomide and pomalidomide product information for details of the pregnancy prevention programme.

Lactation

Elotuzumab is contraindicated during breastfeeding.

The manufacturer recommends that breastfeeding should be stopped during treatment with elotuzumab due to the combination treatment with lenalidomide or pomalidomide. Elotuzumab is not expected to be excreted in human milk however as it is given in combination with lenalidomide or pomalidomide, breastfeeding should be discontinued during treatment.

Side Effects

Anaphylactic reaction
Chest pain
Cough
Deep vein thrombosis (DVT)
Diarrhoea
Fatigue
Headache
Herpes zoster
Hypersensitivity reactions
Hypoaesthesia
Infusion related reaction
Leukopenia
Lymphopenia
Mood changes
Nasopharyngitis
Night sweats
Oropharyngeal pain
Pneumonia
Pyrexia
Upper respiratory tract infection
Weight loss

Overdosage

It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

The following number will direct the caller to the relevant local centre (0844) 892 0111

Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).

Further Information

Last Full Review Date: November 2021

Reference Sources

Summary of Product Characteristics: Empliciti 300mg and 400mg powder for concentrate for solution for infusion. Bristol-Myers Squibb Pharmaceutical Ltd. Revised January 2021.